Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

Zymeworks announced a global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. Zymeworks will receive $55 million upfront and $40 million upon Phase 1b initiation, with potential for up to $718 million in additional milestone payments and tiered royalties on future net sales. Zymeworks will conduct the Phase 1a trial while Roche funds it and handles subsequent development and commercialization.